Tag Archives: Bernard Fortier

GrowPros

Tetra Bio-Pharma Announces the Completion of GrowPros Transaction

Tetra Bio-Pharma Announces the Completion of GrowPros Transaction

OTTAWA, Ontario, Feb. 22, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the completion of the sale of its shares of GrowPros MMP Inc. (“GrowPros”) to North Bud Farms Inc. (the “Purchaser” or “North Bud”) as previously announced in Tetra’s December 21st, 2017 press release.

GrowPros

Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug

OTTAWA, Ontario, Feb. 5, 2018 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.

GrowPros

Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis

OTTAWA, Ontario, Jan. 29, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.

GrowPros

Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary

OTTAWA, Ontario, Jan. 2, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement”) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors”).

GrowPros

Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application

OTTAWA, Ontario, Dec. 21, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with a private Canadian corporation (the “Purchaser”) and has started a transaction to monetize GrowPros (GrowPros MMP Inc., Tetra’s wholly-owned subsidiary) (the “Potential Transaction”), to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical business.

GrowPros

Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony

OTTAWA, Ontario, Dec. 6, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, is pleased to announce that Tetra opened the Toronto Stock Exchange (“TSX”) yesterday at a ceremony to recognize the listing and trading of Tetra, which began on August 16th 2017 under the symbol TBP.

GrowPros

Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device

OTTAWA, Ontario, Nov. 9, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps(TM) inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps(TM).

GrowPros

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

OTTAWA, Ontario, Oct. 26, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

GrowPros

Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

OTTAWA, Ontario, Oct. 18, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR).

GrowPros

Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18

OTTAWA, Ontario, Oct. 4, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel.

GrowPros

Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market

OTTAWA, Ontario, Sept. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.

GrowPros

Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference – BioPharm America

OTTAWA, Ontario, Sept. 8, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities

OTTAWA, Ontario, Aug. 29, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017.

GrowPros

Tetra Bio-Pharma’s Clinical Research Partner, Altasciences, offers Innovative Cannabis Research Solutions

OTTAWA, Ontario, Aug. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and Altasciences are pleased to share that they are in the final stages of completing the world’s first safety and tolerability study on a cannabis extract being developed as a new chemical entity for approval by the FDA and Health Canada as a drug.

GrowPros

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

OTTAWA, Ontario, Aug. 16, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (” Tetra ” or the ” Company “) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE).

GrowPros

Tetra Bio-Pharma Announces Stock Option Grant to CEO

OTTAWA, Ontario, July 25, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company.

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

OTTAWA, Ontario July 24, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017.


Top